J&J unit says its Crohn's disease drug produces better results

10/7/2008 | San Diego Union-Tribune

Crohn's disease patients treated with injections of Remicade -- a biotech drug from Johnson & Johnson's Centocor unit -- alone or along with azathioprine pills were more likely to lose symptoms and discontinue the use of steroids compared with those who received only azathioprine, a company-funded study found. Patients will be evaluated for a year to determine whether the drug can help them avoid bowel surgery, a consultant to Centocor said.

View Full Article in:

San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
Boise, ID